FIGURE 1.

Trial design—Times shown are representative of the window within which each visit occurred: screening took place within 35 days of Visit 2; Visits 2 and 3 occurred on Days 1 and 4, respectively; Visits 4 and 5 were conducted at Day 8 and Week 2, respectively ±2 days; Visit 6 occurred at Week 4 ±4 days; Visit 7 was at Week 8 ±7 days.

*Represents actual sample size—one patient in the trunk and extremities group was excluded from the full analysis set because of incorrect dose assignment.

AK: actinic keratosis; LSR: local skin response